June 10th, 2011
Advancing the Science at ASCO—Metastatic Prostate Cancer
By Vicki Vakiener, Vice President, Sales & Marketing, Veridex, LLC
Our mission is to care for the world, one patient at a time. As we focus on defeating life-threatening diseases such as cancer, we realize it is our collective knowledge and advanced science that will help us successfully tackle this hefty goal.
Over the past decade, I’ve seen an increase in internal and external collaborations that help us to accelerate the development of novel medicines, diagnostic tools and treatment solutions for patients worldwide. When I can find and apply the best science, I know I’m delivering on our heritage and serving the patients who rely on our solutions to be healthier, feel better and live longer, everyday.
To that end, I was pleased to see the collaborative efforts of our diagnostic and pharmaceutical teams at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting earlier this week. Together, Ortho Clinical Diagnostics, Inc. and Centocor Ortho Biotech Inc. utilized their expertise to advance the science of metastatic prostate cancer, where there is still an unmet medical need for diagnostic tools and therapies.
While there is still work to be done, I’m pleased at the progress our company has made thus far. Prostate cancer is a debilitating disease and the second most frequently diagnosed cancer in men in the United States. It is my hope that through our continued efforts, we can help to change the outcomes for the nearly 32,000 men who lose their battle with this disease each year (1).
(1 American Cancer Society)
For more information on our innovations discussed at ASCO, please go here.